OncologySolid Tumors

Radioligand Therapy as a Platform: Beyond PSMA to SSTR, FAPI, and Solid Tumors

Novartis proved the concept. Now 20 companies are building the infrastructure

SR-2026-017

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Radioligand Therapy as a Platform: Beyond PSMA to SSTR, FAPI, and Solid Tumors

Novartis proved the concept. Now 20 companies are building the infrastructure

Why We Are Covering This

Radioligand therapy is expanding well beyond prostate cancer, with FAPI-targeted agents and new isotopes entering Phase 2 trials across multiple solid tumors. Infrastructure is now the primary constraint, and industry is actively racing to solve it.

What to Expect

You will understand the biology of each RLT target beyond PSMA, the clinical rationale for choosing lutetium versus actinium, and what hot lab and dosimetry infrastructure requirements mean for nuclear medicine programs entering this space.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-01707/26

Solid Tumors

Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging

Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.

Prostatic Neoplasms

Prostate Care: Balancing Immediate Relief with Long-Term Retreatment

Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.

Breast Neoplasms

Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy

A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.

Breast Neoplasms

Giredestrant Improves Breast Cancer Survival Regardless of Menopause

Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.

Radioligand Therapy as a Platform: Beyond PSMA to SSTR, FAPI, and Solid Tumors

Radioligand Therapy as a Platform: Beyond PSMA to SSTR, FAPI, and Solid Tumors

Be first when this report publishes

Related Articles